According to a document submitted to the U.S. Securities and Exchange Commission (SEC), some existing shareholders of biotechnology company Kymera Therapeutics, Inc. plan to sell a total of 31.39 million shares of the company's common stock.

According to a document submitted to the U.S. Securities and Exchange Commission (SEC), some existing shareholders of biotechnology company Kymera Therapeutics, Inc. plan to sell a total of 31.39 million shares of the company's common stock.

老虎证券2026/02/26 13:30

Show original

This share sale is initiated by the company's shareholders, rather than through the issuance of new shares by the company itself. Therefore, Kymera Therapeutics will not receive any proceeds from this sale. Such shareholder reductions typically draw market attention to the future supply of the company's stock and potential price volatility. Investors should closely monitor subsequent market developments and related announcements.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops

Lock your assets and earn 10%+ APR

Lock now!

According to a document submitted to the U.S. Securities and Exchange Commission (SEC), some existing shareholders of biotechnology company Kymera Therapeutics, Inc. plan to sell a total of 31.39 million shares of the company's common stock.

You may also like

Trending news

Crypto prices